MRKR Stock Forecast: Marker Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Marker Therapeutics, Inc. is $8. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 76 of 100 as at 21 Nov 2026 — inside the top quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Marker Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (85): Sales and profits are climbing, and climbing faster than before.
Quality (25): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
MRKR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MRKR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 19 most recent actions, 1 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Dec 2025 | HC Wainwright & Co. | Initiates | Buy | $10 |
| 1 Apr 2025 | WBB Securities | Reiterates | Strong Buy | — |
| 5 Mar 2025 | Canaccord Genuity | Initiates | Buy | — |
| 21 Oct 2024 | Ladenburg Thalmann | Maintains | Buy | $11 → $19 |
| 30 Apr 2024 | Ladenburg Thalmann | Initiates | Buy | — |
| 17 Feb 2022 | Roth Capital | Downgrade | Neutral | $3.00 → $1.00 |
| 25 Mar 2021 | Piper Sandler | Initiates | Overweight | — |
| 19 Mar 2021 | Cantor Fitzgerald | Initiates | Overweight | — |
| 18 Mar 2021 | Cantor Fitzgerald | Initiates | Overweight | — |
| 12 May 2020 | Piper Sandler | Downgrade | Neutral | $5.00 → $2.50 |
| 13 Nov 2019 | Janney Capital | Maintains | Buy | — |
| 13 Nov 2019 | Janney Montgomery Scott | Maintains | Buy | $15 → $10 |
| 13 Nov 2019 | Piper Jaffray | Maintains | Overweight | — |
| 13 Nov 2019 | Piper Sandler | Maintains | Overweight | $10 → $6.00 |
| 3 July 2019 | Oppenheimer | Initiates | Outperform | — |
| 30 May 2019 | Roth Capital | Initiates | Buy | — |
| 29 Mar 2019 | WBB Securities | Upgrade | Strong Buy | — |
| 1 Mar 2019 | Janney Capital | Initiates | Buy | — |
| 1 Mar 2019 | Janney Montgomery Scott | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MRKR.
This page is one stock. Monday covers all of them.
MRKR appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
MRKR vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Marker Therapeutics, Inc. returned +12.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MRKR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 9.2×
- Price / book
- 2.0×
- EV / EBITDA
- —
Cheaper than 12% of US stocks
Cheaper than 43% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −59.2%
- Return on assets
- −38.7%
- Dividend yield
- —
Higher than 20% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Marker Therapeutics, Inc. has a market value of $22.0M and an enterprise value of $13.0M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$8.7M.
Free cash flow in the twelve months to 30 June 2026: −$9.8M.
Marker Therapeutics, Inc. employs 5 people.
Data provided by Twelve Data
MRKR and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at MRKR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Marker Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about MRKR
What is the MRKR stock price forecast for 2026-2027?
The median 12-month analyst price target for Marker Therapeutics, Inc. is $8, with estimates ranging from $5.6 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MRKR stock a buy right now?
Of the 3 analysts covering Marker Therapeutics, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Marker Therapeutics, Inc. 76 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MRKR?
As at 21 Nov 2026, Marker Therapeutics, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).
Will MRKR stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts is $8, and Ticker Nerd's factor model ranks Marker Therapeutics, Inc. 76 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MRKR stock forecast for 2030?
No analyst covering Marker Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MRKR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.6 to $10 over the next 12 months.
How has MRKR stock performed over the past year?
Marker Therapeutics, Inc. returned +12.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Marker Therapeutics, Inc. do?
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing T cell-based immunotherapies for blood cancers and solid tumors. Its core platform uses non-genetically engineered tumor-specific T cells designed to recognize multiple tumor-associated antigens, with the goal of creating broader anti-cancer activity.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing T cell-based immunotherapies for blood cancers and solid tumors. Its core platform uses non-genetically engineered tumor-specific T cells designed to recognize multiple tumor-associated antigens, with the goal of creating broader anti-cancer activity. The company’s current pipeline includes product candidates such as MT-601, being studied in lymphoma and pancreatic cancer, and MT-401-OTS, being evaluated in acute myeloid leukemia and myelodysplastic syndromes. Marker Therapeutics also explores peptide-based vaccine approaches as part of its cancer treatment portfolio. Headquartered in Houston, Texas, the company operates in the biotechnology sector and serves the specialized area of cell therapy research and development, where its work supports the advancement of next-generation treatments for difficult-to-treat malignancies.
CEO Dr. Juan F. Vera M.D. · 5 employees · United States · https://markertherapeutics.com